Dermisonics Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Dermisonics prevailing Real Value cannot be determined due to lack of data. The current price of Dermisonics is $0.0. Our model computes the value of Dermisonics from reviewing the firm fundamentals such as Net Income of (5.08 M), current valuation of 63.91 K, and Price To Earning of (0.02) X as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Dermisonics' price fluctuation is out of control at this time. Calculation of the real value of Dermisonics is based on 3 months time horizon. Increasing Dermisonics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dermisonics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dermisonics Stock. However, Dermisonics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 |
The intrinsic value of Dermisonics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Dermisonics' stock price.
Estimating the potential upside or downside of Dermisonics helps investors to forecast how Dermisonics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dermisonics more accurately as focusing exclusively on Dermisonics' fundamentals will not take into account other important factors: Dermisonics Total Value Analysis
Dermisonics is currently projected to have valuation of 63.91 K with market capitalization of 1.92 K, debt of 2.56 M, and cash on hands of 22.77 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Dermisonics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
63.91 K | 1.92 K | 2.56 M | 22.77 K |
Dermisonics Asset Utilization
One of the ways to look at asset utilization of Dermisonics is to check how much profit was generated for every dollar of assets it reports. Dermisonics shows a negative utilization of assets of -0.12 percent, losing $0.001206 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Dermisonics shows how discouraging it operates for each dollar spent on its assets.Dermisonics Profitability Analysis
Net Loss for the year was (5.08 M) with profit before overhead, payroll, taxes, and interest of 0.About Dermisonics Valuation
An absolute valuation paradigm, as applied to Dermisonics Stock, attempts to find the value of Dermisonics based on its fundamental and basic technical indicators. By analyzing Dermisonics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Dermisonics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Dermisonics. We calculate exposure to Dermisonics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dermisonics's related companies.Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. Dermisonics, Inc. was founded in 2000 and is based in Irvine, California. Dermisonics is traded on OTC Exchange in the United States.
Complementary Tools for Dermisonics Stock analysis
When running Dermisonics' price analysis, check to measure Dermisonics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermisonics is operating at the current time. Most of Dermisonics' value examination focuses on studying past and present price action to predict the probability of Dermisonics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermisonics' price. Additionally, you may evaluate how the addition of Dermisonics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |